Ustekinumab, a monoclonal antibody, is approved for the treatment of psoriasis vulgaris and psoriatic arthritis.

In this Healio Video Perspective, Michael A. Singer, MD, discusses promising results for migaldendranib for the treatment of ...

Biocon shares rose over 2 per cent after Biocon Biologics' Japanese commercial partner launched Ustekinumab BS Subcutaneous ...

Biocon had entered into a settlement and licensing agreement with Janssen Biotech Inc, Janssen Sciences Ireland and Johnson & ...

Biocon Biologics and Yoshindo expand access to ustekinumab biosimilar in Japan: Our Bureau, Bengaluru Wednesday, May 21, 2025, 15:15 Hrs [IST] Biocon Biologics a fully integrated ...

Ashvattha Therapeutics reveals promising phase 2 results for migaldendranib, showcasing significant improvements in retinal disease treatment and reduced injection burden.

A domestic study has demonstrated the effect of deoxycholic acid (DCA), the main component of fat-destroying injections, on ...